RecruitingPhase 4NCT07790211

BL-RX01-TFSTAB-1402

A Single Center, Open-Label Study to Evaluate the Ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to Detect Tear Film Stability Utilizing Miebo®


Sponsor

Vance Thompson Vision

Enrollment

20 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

A study to investigate the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo®


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Determine the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo® for people with dry eye. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDetermine the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo®

Determine the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo® by examining potential differences in various tear film assessments before dosing Miebo® and at multiple timepoints post-Miebo® dosing


Locations(1)

Vance Thompson Vision

Sioux Falls, South Dakota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07790211


Related Trials